BOSTON, November 29, 2022 – Proskauer, a leading international law firm, is delighted to announce that partner Fangli Chen, Ph. D., has been named a 2023 Global Leader by IAM Patent, a showcase of the world’s top private practice experts in the field of patents. Earlier this year, IAM also recognized Fangli in its 2022 Strategy 300 Global Leader list.
Fangli, who serves as vice-chair of the Firm’s Life Sciences Patent practice, represents all types of companies across the biotech and pharmaceutical industries and brings a unique blend of patent prosecution, litigation expertise and deep scientific acumen. Her practice focuses on complex portfolio development, post-grant review before the USPTO, oppositions, pre-litigation and litigation strategy, due-diligence investigations, freedom-to-operate, non-infringement and invalidity analysis, licensing and other IP matters in connection with commercial transactions.
To be an IAM Global Leader, an individual must be ranked in the gold tier of the IAM Patent 1000, the market-leading annual directory that identifies the top law firms and individuals in the world’s most important patent jurisdictions. Rankings are based on detailed research conducted by IAM over a four-month period and includes a survey of activities, interviews, and correspondence with patent lawyers, attorneys and their clients.
We are 800+ lawyers serving clients from 12 offices located in the leading financial and business centers in the Americas, Europe and Asia. The world’s leading organizations, companies and corporations choose us to be their representatives in their most critical situations. But more, they consider Proskauer a strategic partner to drive their business forward. We work with asset managers, major sports leagues, Fortune 500 companies, entertainment industry legends and other industry-redefining companies.
Our sophisticated patent team adds value at every stage of the patent development and protection process. Noted for delivering exceptional results, we assist our clients in patent litigation, portfolio development, licensing, technology transfer and strategic counseling. We are one of the few major firms that take plaintiffs' side portfolio work, litigation and licensing, and consistently do it well.